Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019

Abstract A new syndrome called the ‘motoric–cognitive risk’ (MCR) syndrome has recently been proposed in older persons. According to this definition, the parallel impairment in muscle and brain function is more predictive for identifying subjects at risk of dementia than impairment a in single syste...

Full description

Bibliographic Details
Main Authors: Marcello Maggio, Fulvio Lauretani
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Online Access:https://doi.org/10.1002/jcsm.12476
id doaj-b96a06b82f1e41488325095b76069d7d
record_format Article
spelling doaj-b96a06b82f1e41488325095b76069d7d2020-11-25T01:16:23ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092019-10-0110595395510.1002/jcsm.12476Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019Marcello Maggio0Fulvio Lauretani1Geriatric Clinic Unit, Medicine and Geriatric‐Rehabilitation Department, and Department of Medicine and Surgery University of Parma, University Hospital of Parma Parma ItalyGeriatric Clinic Unit, Medicine and Geriatric‐Rehabilitation Department, and Department of Medicine and Surgery University of Parma, University Hospital of Parma Parma ItalyAbstract A new syndrome called the ‘motoric–cognitive risk’ (MCR) syndrome has recently been proposed in older persons. According to this definition, the parallel impairment in muscle and brain function is more predictive for identifying subjects at risk of dementia than impairment a in single system alone. Epidemiological studies suggest that among older persons, enrolled in worldwide population‐based studies, 10% are affected by this syndrome, which confers a higher risk of future disability. In detail, the prevalence of MCR in Europe is around 8.0%, 7.0% in the United States, and 6.3% in Japan. The incidence of the MCR syndrome is estimated to be 65.2 per 1000 person years in adults aged 60 years or older. Many studies reported negative outcomes of the syndrome in older persons, emphasizing its clinical impact. In particular, in almost all longitudinal studies, MCR produces a three‐time increased risk of future dementia. In Europe, data from the InCHIANTI study report an increased risk of 2.74 [1.54–4.86], which is 2.49 [1.52–4.10] in the United States and 3.27 [1.55–6.90] in Japan. The studies in different continents are also consistent in showing an increased risk of all‐cause mortality, which is 1.50–1.87 in the Europeans and 1.69 [1.08–2.02] for incident disability in Japan. For the identification of the MCR syndrome, different tests and procedures have been proposed, with a final ‘core‐battery’ that includes gait speed, dual‐task gait speed, the Montreal Cognitive Assessment and Trail Making Test A and B. The criteria used to select this core‐battery were based on the best accuracy for identifying older persons at risk of negative outcomes such as dementia, falls, aging‐related disabilities, and sensitivity to interventions. The selection of these tests will allow to start studies aimed to better capture older persons at higher risk of mobility and cognitive disability. By these tests, it will be possible to better evaluate the effect of treatment composing of tailored physical exercise, nutritional suggestions, and medical therapy to overturn negative effect of both cognitive and motoric frailty. This article provides an overview of the current knowledge of the MCR syndrome.https://doi.org/10.1002/jcsm.12476Cognitive–motoric risk syndromeOlder personsFacts and numbers
collection DOAJ
language English
format Article
sources DOAJ
author Marcello Maggio
Fulvio Lauretani
spellingShingle Marcello Maggio
Fulvio Lauretani
Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
Journal of Cachexia, Sarcopenia and Muscle
Cognitive–motoric risk syndrome
Older persons
Facts and numbers
author_facet Marcello Maggio
Fulvio Lauretani
author_sort Marcello Maggio
title Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
title_short Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
title_full Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
title_fullStr Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
title_full_unstemmed Prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in Europe, USA, and Japan: facts and numbers update 2019
title_sort prevalence, incidence, and clinical impact of cognitive–motoric risk syndrome in europe, usa, and japan: facts and numbers update 2019
publisher Wiley
series Journal of Cachexia, Sarcopenia and Muscle
issn 2190-5991
2190-6009
publishDate 2019-10-01
description Abstract A new syndrome called the ‘motoric–cognitive risk’ (MCR) syndrome has recently been proposed in older persons. According to this definition, the parallel impairment in muscle and brain function is more predictive for identifying subjects at risk of dementia than impairment a in single system alone. Epidemiological studies suggest that among older persons, enrolled in worldwide population‐based studies, 10% are affected by this syndrome, which confers a higher risk of future disability. In detail, the prevalence of MCR in Europe is around 8.0%, 7.0% in the United States, and 6.3% in Japan. The incidence of the MCR syndrome is estimated to be 65.2 per 1000 person years in adults aged 60 years or older. Many studies reported negative outcomes of the syndrome in older persons, emphasizing its clinical impact. In particular, in almost all longitudinal studies, MCR produces a three‐time increased risk of future dementia. In Europe, data from the InCHIANTI study report an increased risk of 2.74 [1.54–4.86], which is 2.49 [1.52–4.10] in the United States and 3.27 [1.55–6.90] in Japan. The studies in different continents are also consistent in showing an increased risk of all‐cause mortality, which is 1.50–1.87 in the Europeans and 1.69 [1.08–2.02] for incident disability in Japan. For the identification of the MCR syndrome, different tests and procedures have been proposed, with a final ‘core‐battery’ that includes gait speed, dual‐task gait speed, the Montreal Cognitive Assessment and Trail Making Test A and B. The criteria used to select this core‐battery were based on the best accuracy for identifying older persons at risk of negative outcomes such as dementia, falls, aging‐related disabilities, and sensitivity to interventions. The selection of these tests will allow to start studies aimed to better capture older persons at higher risk of mobility and cognitive disability. By these tests, it will be possible to better evaluate the effect of treatment composing of tailored physical exercise, nutritional suggestions, and medical therapy to overturn negative effect of both cognitive and motoric frailty. This article provides an overview of the current knowledge of the MCR syndrome.
topic Cognitive–motoric risk syndrome
Older persons
Facts and numbers
url https://doi.org/10.1002/jcsm.12476
work_keys_str_mv AT marcellomaggio prevalenceincidenceandclinicalimpactofcognitivemotoricrisksyndromeineuropeusaandjapanfactsandnumbersupdate2019
AT fulviolauretani prevalenceincidenceandclinicalimpactofcognitivemotoricrisksyndromeineuropeusaandjapanfactsandnumbersupdate2019
_version_ 1725149928028635136